Antibody to ras proteins in patients with colon cancer

M. Takahashi, W. Chen, D. R. Byrd, M. L. Disis, E. S. Huseby, H. Qin, L. McCahill, Heidi Nelson, H. Shimada, K. Okuno, M. Yasutomi, D. J. Peace, M. A. Cheever

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The current study examined sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present. Studies focused on the aspartic acid substitution at amino acid position 12 (denoted D12), one of the most common mutations in colon adenocarcinoma. IgA antibodies directed against mutated p21 ras-D12 protein were detected in 51 (32%) of 160 colon cancer patients, but only in 1 (2.5%) of 40 normal individuals. The greater incidence of antibody in cancer patients provides presumptive evidence that immunization to the ras proteins occurred as a result of the malignancy. Examination of sera for antibody reactivity to wild-type p21 ras protein (denoted p21 ras-G12) as well as p21 ras proteins bearing the D12, V12, S12, or L61 mutations showed that antibody detected was largely to normal segments of the p21 ras protein. Epitope mapping, using peptide neutralization assays with mutated or normal ras peptides as competitors, demonstrated that in 10 (67%) of 15 sera examined the antibody reactivity to p21 ras-G12 protein was neutralized by peptides near the carboxyl terminus of p21 ras protein, but not by peptides spanning the specific point mutation region. Antibody reactivities correlated with peripheral blood lymphocyte count, but did not correlate with patient age, sex, histology, stage, tumor locus, lymph node metastasis, or scrum carcinoembryonic antigen.

Original languageEnglish (US)
Pages (from-to)1071-1077
Number of pages7
JournalClinical Cancer Research
Volume1
Issue number10
StatePublished - 1995

Fingerprint

Proto-Oncogene Proteins p21(ras)
ras Proteins
Colonic Neoplasms
Antibodies
Peptides
G12-G13 GTP-Binding Protein alpha Subunits
Serum
Epitope Mapping
Neoplasms
Mutation
Carcinoembryonic Antigen
Lymphocyte Count
Amino Acid Substitution
Point Mutation
Aspartic Acid
Immunoglobulin A
Immunization
Histology
Colon
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Takahashi, M., Chen, W., Byrd, D. R., Disis, M. L., Huseby, E. S., Qin, H., ... Cheever, M. A. (1995). Antibody to ras proteins in patients with colon cancer. Clinical Cancer Research, 1(10), 1071-1077.

Antibody to ras proteins in patients with colon cancer. / Takahashi, M.; Chen, W.; Byrd, D. R.; Disis, M. L.; Huseby, E. S.; Qin, H.; McCahill, L.; Nelson, Heidi; Shimada, H.; Okuno, K.; Yasutomi, M.; Peace, D. J.; Cheever, M. A.

In: Clinical Cancer Research, Vol. 1, No. 10, 1995, p. 1071-1077.

Research output: Contribution to journalArticle

Takahashi, M, Chen, W, Byrd, DR, Disis, ML, Huseby, ES, Qin, H, McCahill, L, Nelson, H, Shimada, H, Okuno, K, Yasutomi, M, Peace, DJ & Cheever, MA 1995, 'Antibody to ras proteins in patients with colon cancer', Clinical Cancer Research, vol. 1, no. 10, pp. 1071-1077.
Takahashi M, Chen W, Byrd DR, Disis ML, Huseby ES, Qin H et al. Antibody to ras proteins in patients with colon cancer. Clinical Cancer Research. 1995;1(10):1071-1077.
Takahashi, M. ; Chen, W. ; Byrd, D. R. ; Disis, M. L. ; Huseby, E. S. ; Qin, H. ; McCahill, L. ; Nelson, Heidi ; Shimada, H. ; Okuno, K. ; Yasutomi, M. ; Peace, D. J. ; Cheever, M. A. / Antibody to ras proteins in patients with colon cancer. In: Clinical Cancer Research. 1995 ; Vol. 1, No. 10. pp. 1071-1077.
@article{5f356aabd78f496da94acfef97f65d96,
title = "Antibody to ras proteins in patients with colon cancer",
abstract = "The current study examined sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present. Studies focused on the aspartic acid substitution at amino acid position 12 (denoted D12), one of the most common mutations in colon adenocarcinoma. IgA antibodies directed against mutated p21 ras-D12 protein were detected in 51 (32{\%}) of 160 colon cancer patients, but only in 1 (2.5{\%}) of 40 normal individuals. The greater incidence of antibody in cancer patients provides presumptive evidence that immunization to the ras proteins occurred as a result of the malignancy. Examination of sera for antibody reactivity to wild-type p21 ras protein (denoted p21 ras-G12) as well as p21 ras proteins bearing the D12, V12, S12, or L61 mutations showed that antibody detected was largely to normal segments of the p21 ras protein. Epitope mapping, using peptide neutralization assays with mutated or normal ras peptides as competitors, demonstrated that in 10 (67{\%}) of 15 sera examined the antibody reactivity to p21 ras-G12 protein was neutralized by peptides near the carboxyl terminus of p21 ras protein, but not by peptides spanning the specific point mutation region. Antibody reactivities correlated with peripheral blood lymphocyte count, but did not correlate with patient age, sex, histology, stage, tumor locus, lymph node metastasis, or scrum carcinoembryonic antigen.",
author = "M. Takahashi and W. Chen and Byrd, {D. R.} and Disis, {M. L.} and Huseby, {E. S.} and H. Qin and L. McCahill and Heidi Nelson and H. Shimada and K. Okuno and M. Yasutomi and Peace, {D. J.} and Cheever, {M. A.}",
year = "1995",
language = "English (US)",
volume = "1",
pages = "1071--1077",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Antibody to ras proteins in patients with colon cancer

AU - Takahashi, M.

AU - Chen, W.

AU - Byrd, D. R.

AU - Disis, M. L.

AU - Huseby, E. S.

AU - Qin, H.

AU - McCahill, L.

AU - Nelson, Heidi

AU - Shimada, H.

AU - Okuno, K.

AU - Yasutomi, M.

AU - Peace, D. J.

AU - Cheever, M. A.

PY - 1995

Y1 - 1995

N2 - The current study examined sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present. Studies focused on the aspartic acid substitution at amino acid position 12 (denoted D12), one of the most common mutations in colon adenocarcinoma. IgA antibodies directed against mutated p21 ras-D12 protein were detected in 51 (32%) of 160 colon cancer patients, but only in 1 (2.5%) of 40 normal individuals. The greater incidence of antibody in cancer patients provides presumptive evidence that immunization to the ras proteins occurred as a result of the malignancy. Examination of sera for antibody reactivity to wild-type p21 ras protein (denoted p21 ras-G12) as well as p21 ras proteins bearing the D12, V12, S12, or L61 mutations showed that antibody detected was largely to normal segments of the p21 ras protein. Epitope mapping, using peptide neutralization assays with mutated or normal ras peptides as competitors, demonstrated that in 10 (67%) of 15 sera examined the antibody reactivity to p21 ras-G12 protein was neutralized by peptides near the carboxyl terminus of p21 ras protein, but not by peptides spanning the specific point mutation region. Antibody reactivities correlated with peripheral blood lymphocyte count, but did not correlate with patient age, sex, histology, stage, tumor locus, lymph node metastasis, or scrum carcinoembryonic antigen.

AB - The current study examined sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present. Studies focused on the aspartic acid substitution at amino acid position 12 (denoted D12), one of the most common mutations in colon adenocarcinoma. IgA antibodies directed against mutated p21 ras-D12 protein were detected in 51 (32%) of 160 colon cancer patients, but only in 1 (2.5%) of 40 normal individuals. The greater incidence of antibody in cancer patients provides presumptive evidence that immunization to the ras proteins occurred as a result of the malignancy. Examination of sera for antibody reactivity to wild-type p21 ras protein (denoted p21 ras-G12) as well as p21 ras proteins bearing the D12, V12, S12, or L61 mutations showed that antibody detected was largely to normal segments of the p21 ras protein. Epitope mapping, using peptide neutralization assays with mutated or normal ras peptides as competitors, demonstrated that in 10 (67%) of 15 sera examined the antibody reactivity to p21 ras-G12 protein was neutralized by peptides near the carboxyl terminus of p21 ras protein, but not by peptides spanning the specific point mutation region. Antibody reactivities correlated with peripheral blood lymphocyte count, but did not correlate with patient age, sex, histology, stage, tumor locus, lymph node metastasis, or scrum carcinoembryonic antigen.

UR - http://www.scopus.com/inward/record.url?scp=0028832188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028832188&partnerID=8YFLogxK

M3 - Article

C2 - 9815896

AN - SCOPUS:0028832188

VL - 1

SP - 1071

EP - 1077

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -